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Abstract
The epidemic of USA300-0114 methicillin-resistant Staphylococcus aureus (MRSA) in the USA has been remarkable for its virulence and
for its ability to cause infections in both the community and healthcare settings. Although it has mainly been associated with skin and
soft tissue infections, particularly furunculosis, it has also caused severe life-threatening conditions such as necrotizing pneumonia, osteo-
myelitis, and septic arthritis. This strain or a closely related Latin American variant has now spread to multiple countries on five conti-
nents, where associated clinical and epidemiological features have been in keeping with those seen in the USA. Furthermore, it has
become the dominant community-associated MRSA strain in five countries. It is now a major international epidemic strain, but whether
it will supplant established community-associated strains in other countries remains to be seen.
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The epidemiology of Staphylococcus aureus has changed
remarkably in the early 21st century, with the rapid simulta-
neous emergence of virulent community-associated methicil-
lin-resistant S. aureus (CA-MRSA) strains around the world
[1]. Perhaps the most notable and well-documented epidemic
has been that in the USA, caused by the USA300 strain.
The name USA300 was coined to describe the pulsed-field
gel electrophoresis (PFGE) pattern of one of a number of
methicillin-resistant S. aureus (MRSA) strains identified in the
USA [2]. USA300 comprised a cluster of closely related
PFGE patterns, including one variant, USA300-0114, that has
been dominant in the CA-MRSA epidemic in the USA [3].
All variants belonged to ST8-MRSA-IV according to multilo-
cus sequence typing and staphylococcal chromosomal cas-
sette mec (SCCmec) typing. Outbreaks of USA300 began as
early as 1999 in distinct populations such as prisoners, chil-
dren in day care, athletes (particularly participants in contact
sports), and military recruits, and also in community settings
in otherwise healthy young people [4]. The infections associ-
ated with it included moderate to severe skin and soft tissue
infections (SSTIs) and invasive infections, including necrotizing
pneumonia, bone and joint infections, and necrotizing fasci-
itis.
The USA300 MRSA epidemic within the USA has been
remarkable for the rapidity of its spread within the
community, for its virulence, and for its subsequent emer-
gence as a major cause of healthcare-associated (HA) infec-
tion [5–8]. The latter trend is of particular concern, as two
independently developed mathematical models predict that
successful CA-MRSA clones will come to dominate in health-
care settings [9,10]. The spread of USA300 has frequently
been associated with fomites, and a number of studies sug-
gest that it also has enhanced environmental survival and
transmission properties [11–13]. Thus, USA300 is well
adapted to spread and cause infections in the community
and healthcare settings. This review will examine its impact
beyond the borders of the USA.
Definitions
Although USA300 was originally defined by related PFGE
patterns with >80% similarity [4], a number of other features
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define its epidemic methicillin-resistant variants. USA300-
0114 and closely related variants predominantly carry the
IVa subtype of SCCmec, spa type YHGFMBQBLO (t008;
Ridom SpaServer), msrA-mediated macrolide resistance, and
a number of virulence genes, including lukS-PV/lukF-PV and
arcA, coding for Panton–Valentine leukocidin (PVL) and the
arginine catabolic mobile element, respectively [3,14].
Isolates sharing these characteristics will be referred to as
‘USA300-0114’. A separate group of variants with six or
fewer band differences on PFGE has been reported in Latin
America, with the following characteristics: ST8, predomi-
nantly SCCmec type IVc, spa type t008, lukS-PV/lukF-PV pres-
ent, arcA absent, and, commonly, tetracycline resistant
caused by tetK [15]. This Latin American variant will be
referred to as ‘USA300-LV’. Where typical PFGE, multilocus
sequence typing or spa typing results and the presence of
PVL genes are provided but SCCmec subtyping and the pres-
ence of arcA are not, isolates will be presumed to be
USA300, and designated ‘USA300-P’.
Community-onset (CO) infections will, if possible, be
divided into those without HA risk factors (CO-NR) and
those with HA risk factors (CO-RF). The term hospital-
onset (HO) will be used for infections occurring after 48 or
72 h of hospitalization as defined by the authors.
Canada
In Canada, USA300 is known as CMRSA-10, and has been
the dominant CA-MRSA strain since 2004 [16–18]. An early
report stated that USA300-P accounted for 16% of new
cases in a study of MRSA infection or colonization in aborigi-
nal hospital inpatients conducted from 1995 to 2002,
although the year of first isolation was not stated [19].
Although it probably spread to Canada from the USA, most
reported cases are autochthonous, where acquisition details
are recorded [20–22]. In studies where isolates have under-
gone full molecular characterization, CMRSA-10 has been
indistinguishable from USA300-0114 (Table 1). Although ini-
tially more prevalent in western Canada, it has become pre-
dominant in eastern centres as well [16,20,23]. Susceptibility
to most non-b-lactam antimicrobials has been the norm.
However, the majority of isolates have been resistant to
erythromycin (but not to lincosamides), and some have also
been resistant to ciprofloxacin [20,22,24–27].
As in the USA, infection mainly manifests as moderate to
severe SSTI, particularly furunculosis [20–23,28], and is more
common among children and young adults [16,23,25]. Inva-
sive infection has been reported less frequently, but has
included cases of necrotizing pneumonia, empyema, bactera-
emia, and infectious endocarditis [22,24,27,28]. An extensive
outbreak was reported in 2004 in Calgary, Alberta among
individuals with a history of illicit drug use, incarceration, or
homelessness: there were 39 cases of SSTI, and one fatal
case of necrotizing pneumonia [22]. Further investigation
found a prevalence of colonization or infection of 5.5% in
the marginalized population, and increased risk was associ-
ated with shared drug use between sex trade workers and
clients or casual sex partners [21].
A population-based study of S. aureus bacteraemia in Cal-
gary from 2000 to 2006 noted a major shift to CO CMRSA-
10 cases from 2004, with a prevalence of 0.4/100000 [17]. A
national prevalence survey conducted from 2007 to 2009
found that CMRSA-10 was responsible for 73.7% of
CA-MRSA cases, 18.6% of all MRSA cases, and 4.6% of all
S. aureus cases [29]. Another survey of all MRSA infections
in Alberta from July 2005 to June 2008 found that CMRSA-
10 caused 53% of cases and that the population-based preva-
lence was 16/100 000 in 2008 [25]. The proportion of HO
cases in Alberta was 21%. The proportion was even higher
in Vancouver in 2008–2009, with CMRSA-10 accounting for
32% of 126 incident cases of HO-MRSA infection or coloni-
zation [28]. Further evidence of the spread of CMRSA-10
into the healthcare setting is provided by multiple other
reports confirming CO-RF and HO infection (Table 1). One
hospital outbreak involving mothers and babies in a neonatal
unit has also been reported [26]. Overall, the CMRSA-10
epidemic in Canada mirrors the experience with USA300-
0144 in the USA.
Latin America and the Caribbean
The Latin American variant USA300-LV was first identified in
Colombia as early as 2006, following an earlier report of
two cases of CA-MRSA without details of genotyping
[30,31]. Subsequently, USA300-LV has also been reported in
Venezuela, Ecuador, Peru, Trinidad and Tobago, and Argen-
tina (Fig. 1) [15,32–35]. Although USA300-LV is the predomi-
nant variant in these countries, USA300-0114 has also been
reported in low numbers in all of these countries except
Argentina. Autochthonous spread of USA300-LV has been
well documented (Table 1). Imported cases have also been
reported in this region: one caused by USA300-P from the
USA in Brazil, and one each caused by USA300-0114 and
USA300-LV from Puerto Rico and Ecuador, respectively, in
Trinidad and Tobago [33,36]. Four cases of CO-NR infection
and one of CO-RF infection caused by USA300-P have
been reported from Mexico [37]. As the Mexican isolates
showed 88% similarity to USA300-0114 by PFGE, resistance
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to erythromycin, predominant resistance to ciprofloxacin,
and susceptibility to tetracycline, they are probably closely
related to USA300-0114.
Although the majority of cases in Latin America have had
their onset in the community (Table 1), 26 USA300-LV HO
cases have been reported from Colombia [32]. They include
nine cases of bacteraemia and 13 of surgical wound infection,
with an overall mortality of 27%. Half of the patients were
aged ‡60 years, and only 23% were aged <40 years. Where
information has been available regarding CO infection, SSTI,
particularly furunculosis, has predominated, although bactera-
emia has also been reported [31,33,34,37]. Where suscepti-
bility data are available for USA300-LV, resistance to
tetracycline but not to other non-b-lactam antimicrobials is
relatively common [15,32]. While age-related data for CO
USA300-LV infection is generally lacking, the ages of two
reported cases were 3 years and 39 years [33,34]. Although
CA-MRSA accounts for 45% of CO S. aureus infection in
Argentina, USA300-LV is relatively uncommon there, repr-
senting only 1.4% of 500 CO-MRSA isolates from a survey of
infections in children in 2007–2008 [35]. The situation in
Colombia, Ecuador and Venezuela is very different: there,
USA300-LV is the dominant CA-MRSA strain, accounting for
10.6% of consecutive S. aureus isolates in hospital laborato-
ries [15]. Finally, a recent study of porcine carriage of MRSA
has raised the possibility of an animal reservoir: one isolate
of USA300-LV was identified from nasal swabs of 120 rural
scavenging pigs in Peru in 2009 [38].
Europe
USA300 was first recognized in Europe in Denmark in
2000 [39]. Over 50 reports from 15 countries have fol-
lowed, including cases causedby both USA300-0114 and
USA300-LV (Table 1; Fig. 1). While imported cases have
been reported frequently, autochthonous spread of
USA300-0114 has also been recorded in Austria, Denmark,
England, France, Ireland, The Netherlands, and Spain [39–
46]. Autochthonous spread of USA300-LV is more limited,
having been reported in only Italy and Spain [41,44,47,48].
Although USA300 MRSA isolates in Europe have been sus-
ceptible to most non-b-lactam antimicrobials, USA300-0114
isolates have generally been resistant to erythromycin, and
frequently resistant to fluoroquinolones [44,49]. USA300-LV
isolates have been resistant to tetracycline in less than half
of cases, and to mupirocin or fusidic acid occasionally
[44,48]. Although population-based prevalence data have
been lacking, only three (0.3%) isolates from S. aureus bac-
teraemia cases in 26 European countries between Septem-
ber 2006 and February 2007 were consistent with USA300
MRSA [50]. By comparison, only two isolates of ‘European’
ST80 CA-MRSA were detected in the same survey. Isolates
consistent with USA300 are the most common PVL-positive
MRSA strains in Spain, and, among these, USA300-LV is
predominant [41,44,48,51]. Unlike the situation in Canada,
USA300 generally makes up only a small proportion of all
clinical MRSA isolates in Europe, ranging from 0.8% to 3.5%
in various countries [39,44,45,47,51–55].
As elsewhere, furunculosis and other SSTIs have been the
major clinical manifestations of infection with both USA300-
0114 and USA300-LV in Europe [44,45,48,56]. Cases of severe
invasive infection, including necrotizing pneumonia, meningitis,
osteomyelitis, and deep vein thrombosis, have also been
reported [56–61]. One community outbreak caused by
USA300-0114 related to a beauty salon has been reported
from The Netherlands [42]. The great majority of cases have
had their onset in the community, and CO-NR infections are
common among these (Table 1). Although HO cases have
been documented, no hospital outbreaks have been reported.
FIG. 1. Countries outside of the USA with reports of USA300 infection.
CMI Nimmo USA300 abroad: global spread of a virulent strain of CA-MRSA 729
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 725–734
Finally, one remarkable case of USA300-P infection in a dog
has recently been reported from France [62]. The isolate from
a surgical wound infection was arginine catabolic mobile ele-
ment-negative, and therefore may be related to USA300-LV.
However, a family member of the treating veterinarian had
recently undergone prolonged hospitalization in the USA.
SCCmec subtyping was not reported.
Middle East
Two reports of cases of USA300 infection among USA mili-
tary personal have come from combat support hospitals in
Iraq [63,64]. USA300-0114 was definitively identified in one
of them, and constituted 79% of 84 MRSA isolates [64].
Ninety-two per cent of isolates were resistant to erythromy-
cin, 3% to clindamycin, 41% to levofloxacin, and 1% to tetra-
cycline. Most cases have been wound infections and
furunculosis [63]. The only other report from the Middle
East was from the Western Galilee region of Israel. The case
was an autochthonous one consistent with USA300-P resis-
tant only to b-lactams and erythromycin in a 9-month-old
child with post-varicella furunculosis [65].
Western Pacific
USA300-0114 has been reported in the Western Pacific
from China, South Korea, Japan, Australia, New Zealand,
and Samoa (Table 1; Fig. 1). Single cases of imported infec-
tion were reported in South Korea and China in 2004–2005
and 2007, respectively [66,67]. The Chinese case was of
furunculosis in a 39-year-old Japanese man who had recently
visited Thailand and had no HA risk factors. The first
imported case occurring in Japan was in Tokyo in 2007 in a
3-month-old, US-born female with CO furunculosis [68].
Two additional cases occurred in 2008 in Saitama: an
imported CO case of furunculosis and epidural abscess in a
25-year-old American woman, and an autochthonous CO
case of cellulitis and bacteraemia in an 11-month-old girl
[69,70]. Two HA outbreaks have also been reported in
Japan: one in Okinawa in 2008, involving a CO index case
and three healthcare workers, all with furunculosis, and one
in Kyoto in 2009 involving both hospitalized patients and
healthcare workers, including cases of furunculosis, pneumo-
nia, and catheter-related bacteraemia [71,72]. The outbreak
strain in the latter was unusual in being resistant only to
levofloxacin. Where tested, isolates from the other north-
western Asian reports were all resistant to erythromycin.
Some were resistant to ciprofloxacin, and the Okinawa
strain was also resistant to clindamycin, consistent with a
constitutive MLSB phenotype.
USA300 first appeared in Australia in 2003: 76 isolates
from 72 cases in Perth, Western Australia, were collected
between July 2003 and February 2008 [73]. The majority
conformed to USA300-0114, but 12 lacked arcA and were
therefore likely to be USA300-LV. Five of these isolates car-
ried tetK, which is unusual in USA300-0114. Most USA-0114
isolates carried msrA (57/64), as did four USA300-LV isolates.
Most cases (94%) were of SSTI. On the east coast, USA300-
P was reported in 2008 in an imported case of furunculosis
in a US resident visiting Sydney [74]. Two USA300-P isolates
identified in a prevalence survey conducted in Queensland in
2008 represented <0.1% of S. aureus non-duplicate clinical
isolates [74]. Biennial national prevalence surveys of clinical
S. aureus isolates from outpatients conducted from 2000 to
2010 identified USA300-P isolates from 2004 onwards
[75,76]. Most isolates were from New South Wales, but
some were also identified in Queensland, Victoria, Western
Australia, and the Northern Territory. They represented
only 0.8–1.8% of MRSA isolates and 0.1–0.3% of S. aureus
isolates in the various surveys. The six isolates from the
2010 survey were all resistant to erythromycin, one was
additionally resistant to mupirocin, and two were additionally
resistant to ciprofloxacin. They were susceptible to the
remaining 13 non-b-lactam antimicrobials tested.
Prevalence surveys identifying cases of USA300 MRSA
infection have also been conducted in New Zealand and
Samoa. A Samoan study conducted in 2007–2008 showed
that USA300-P represented 29% of 34 MRSA isolates and
5% of 187 S. aureus isolates from autochthonous cases of
SSTI [77]. Of note, it was the most common MRSA strain,
ahead of the Queensland clone (ST93-MRSA-IV–26%) and
the south-western Pacific clone (ST30-MRSA-IV–12%). The
isolates were all resistant to ciprofloxacin, and most were
also resistant to erythromycin. In New Zealand, USA300-P
represented 7.2% of 740 MRSA isolates referred to a refer-
ence laboratory as part of a national survey in 2010 [78].
Fifty-seven per cent of cases were CO-MRSA and 82% of
patients were aged <60 years. USA300-P was first identified
in Dunedin in 2004, and has since been isolated throughout
the country.
Discussion
International and intercontinental spread of epidemic S. aur-
eus strains, including MRSA, is not a new phenomenon
[79,80], but is arguably being facilitated by increasing volumes
of international travel and migration in the 21st century. In
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this context, the rapid international spread of USA300 pro-
vides a good example. Within a few years of its first descrip-
tion, it has been reported in 36 countries on five continents
(Table 1; Fig. 1). Furthermore, autochthonous acquisition has
been documented in Canada, 10 European countries, Colom-
bia, Trinidad and Tobago, Israel, Japan, and Samoa. This has
been a cause for concern, given its virulence and epidemic
potential in both community and healthcare settings in the
USA.
The prevalence of USA300 currently remains low in most
countries. Notable exceptions are Canada, Samoa, and the
Andean countries of Columbia, Ecuador, and Venezuela.
USA300-0114 has become the dominant CA-MRSA strain in
Canada, which is not surprising, given its shared open border
with the USA. It has also been identified definitively in coun-
tries in Europe (10), Latin American (4), the Western Pacific
(4), and the Caribbean (1) (Table 1). The surprisingly high
prevalence of USA300-P in Samoa may similarly be explained
by its proximity to and close cultural links with American
Samoa. Furthermore, many of the isolates there were indis-
tinguishable from the USA300-0114 pulsotype, and had a
resistance profile suggestive of that strain [77]. The Andean
countries, on the other hand, appear to be the epicentre for
the emergence of the variant USA300-LV [15]. It has also
been definitively detected in two other Spanish-speaking
countries in Latin America, in the Caribbean, in six European
countries, and in Australia (Table 1).
The clinical manifestations of USA300-0114, USA300-LV
and USA300-P around the world are all similar to those
experienced in the USA with USA300-0114. As detailed
above, most cases have been of SSTI, particularly furunculo-
sis, but severe invasive infections have also regularly been
reported. Although the mortality rate was remarkably high in
Columbian HO infections, only four other fatal cases have
been reported [22,27,32,43,58]. A predilection for children
and younger adults has been noted frequently. Spread into
healthcare settings has also been frequent, although only
USA300-0114 has been associated with reports of outbreaks
(Table 1). Reports of infection with USA300-P in a dog in
France and of carriage of USA300-LV in a scavenging pig in
Peru were exceptional, although isolations of USA300-0114
from a dog and a pig have also been reported in the USA
[38,62,81].
In conclusion, USA300 MRSA has become a major interna-
tional epidemic clone, commonly causing both CO and HO
infections, and is now the dominant CA-MRSA strain in five
countries outside of the USA. Whether it will replace estab-
lished CA-MRSA in other countries remains to be seen.
Regardless of this, experience to date suggests that the
USA300 epidemic will continue for some time to come.
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